Wendell Pritchett

Synovus Announces Recent Hires and Key Leaders in Corporate & Investment Banking Group

Retrieved on: 
Friday, October 14, 2022
Professional Services, Other Professional Services, Finance, Asset Management, Banking, Personal Finance, LinkedIn, J. P. Morgan, Bank of America, Insurance, Wharton School of the University of Pennsylvania, Sumitomo Mitsui Banking Corporation, Colgate University, CIB, KeyBank, Wendell Pritchett, TMC, Bank, MBA, Twitter, Business, Instagram, Multimedia, Miami University, Kurdistan Region Security Council, Technology, University, Goldman Sachs, Nicolosi, Columbia University, Grantham, Company, Acquisition, Deutsche Bank, Industry, Treasury, West Pharmaceutical Services, Practice management, PNC, Thompson, Lazard, Indiana University of Pennsylvania, FDIC, History of the University of Maryland, College Park, Merrill (company), Financial services, Synovus, Facebook

Synovus Bank today announced additions to its leadership team in its expanding corporate & investment banking (CIB) line of business.

Key Points: 
  • Synovus Bank today announced additions to its leadership team in its expanding corporate & investment banking (CIB) line of business.
  • With nearly 15 years of experience in strategic finance and investment banking, Thompson joined Synovus from Bank of America Securities global healthcare group.
  • Were excited to expand our corporate and investment banking team with these highly experienced and skilled bankers, said Tom Dierdorff, head of corporate & investment banking at Synovus.
  • To learn more about the Synovus corporate and investment banking group, visit https://www.synovus.com/CIB .

PerformLine Appoints Financial Industry Veteran Paul Wilmore as Chief Operating Officer

Retrieved on: 
Tuesday, October 11, 2022
Software, Finance, Marketing, Banking, Communications, Professional Services, Technology, Fintech, Wharton School of the University of Pennsylvania, Sale, Growth, Wendell Pritchett, Omnichannel, Organization, Wilmore, Barclays, MBA, Multimedia, NCR, Automation, University, Marketing, Social media, CMO, Swarthmore College, Compliance, Leadership, Cryptocurrency, Online shopping, Economics, Cardtronics

PerformLine , the only provider of omni-channel marketing compliance software, announced today that Paul Wilmore has joined the company as its first Chief Operating Officer.

Key Points: 
  • PerformLine , the only provider of omni-channel marketing compliance software, announced today that Paul Wilmore has joined the company as its first Chief Operating Officer.
  • Wilmore brings over 30 years of financial services experience along with a proven track record of building and leading financial startups through periods of tremendous growth and profitability.
  • View the full release here: https://www.businesswire.com/news/home/20221010005031/en/
    Wilmore joins the company after having helped lead publicly traded Cardtronics, a trusted leader in financial self-service, through a successful sale to NCR as their Global Chief Marketing Officer.
  • Request a demo to see why PerformLine is the go-to platform leading enterprises choose to power their marketing compliance programs.

Taylor Rosty Named as CEO for Denver Marketing/Fundraising Agency Lasso Digital

Retrieved on: 
Friday, October 7, 2022
Marketing, Wharton School of the University of Pennsylvania, Culture, Government, Growth, Wyoming Department of Education, Connect for Health Colorado, Survivor, Wendell Pritchett, Connect, Domestic violence, Non-governmental organization, University, Software, Modernization theory, CEO, Pál Rosty de Barkóc, Wyoming Department of Environmental Quality, James Parker (art historian), Public health, Management, Asset management, Economics, Science

DENVER, Oct. 7, 2022 /PRNewswire/ -- Lasso Digital is excited to announce the appointment of Taylor Rosty as Chief Executive Officer. Most recently Rosty served as the Managing Director for the firm.

Key Points: 
  • DENVER, Oct. 7, 2022 /PRNewswire/ -- Lasso Digital is excited to announce the appointment of Taylor Rosty as Chief Executive Officer.
  • Before joining Lasso, Rosty held positions at The Blue Bench, a Denver-based nonprofit, and Black Fox Philanthropy, a Boulder-based fundraising consultancy serving global NGOs.
  • "I'm excited and proud to name Taylor CEO of Lasso Digital," said Erich Kirshner, the agency's founder and owner.
  • Lasso Digital, formerly The Evolution Agency, is a Denver marketing and fundraising firm that specializes in meeting the communications needs of nonprofit and government clients.

MedAxiom, Wharton Online Partner to Transform Cardiovascular Business Education

Retrieved on: 
Thursday, October 6, 2022
Cardiology, University, Practice Management, Education, Managed Care, Other Health, Health, General Health, Health Technology, Hospitals, Telemedicine, Virtual Medicine, Online, Wharton School of the University of Pennsylvania, Wendell Pritchett, Education, Program, MBA, Multimedia, Partnership, Knowledge, University, ACC (company), MD, Doctor of Philosophy, Industry, Economics, Faculty, Leadership, FACC, Medicine, Management

MedAxiom, the cardiovascular communitys premier destination for organizational performance solutions, has partnered with Wharton Online to develop a first-of-its-kind business and management program designed specifically for cardiovascular professionals.

Key Points: 
  • MedAxiom, the cardiovascular communitys premier destination for organizational performance solutions, has partnered with Wharton Online to develop a first-of-its-kind business and management program designed specifically for cardiovascular professionals.
  • View the full release here: https://www.businesswire.com/news/home/20221006005270/en/
    The Cardiovascular Business and Management Essentials Program, an exclusive partnership between the Wharton Online and MedAxiom, focuses on the non-clinical competencies of healthcare operations, economics, change leadership and people management.
  • Together, MedAxiom and Wharton Online are building tomorrows cardiovascular business leaders, said MedAxiom President and CEO Jerry Blackwell, MD, MBA, FACC, a lead faculty member for the program.
  • The Wharton Schools digital learning platform Wharton Online makes high-quality business education available to learners anytime and anywhere, in the form of online certificates and specializations across a variety of business and management topics, with the goal of helping learners advance their careers.

Bain & Company and Prysm Group announce collaboration to expand corporate learning on web3 and emerging technologies

Retrieved on: 
Tuesday, October 4, 2022
Wendell Pritchett, Ecosystem, Technology, Research, Industry, Bain & Company, Knowledge, Financial services, Economic development, Adoption, Education, Blockchain, Goal, Platinum, City, Social justice, Environment, Harvard University, Organization, Company, Wharton, Wharton School of the University of Pennsylvania, Public relations, Risk management

BOSTON, Oct. 4, 2022 /PRNewswire/ -- Bain & Company, a top global management consultancy, and Prysm Group, a leading economic consulting and corporate education firm, have announced a collaboration to expand corporate learning on web3 and emerging technologies. By leveraging Bain's extensive consulting network and industry insight, Prysm Group will further refine the strategic messaging used within its executive education program delivered in collaboration with the Wharton School.

Key Points: 
  • BOSTON, Oct.4, 2022 /PRNewswire/ -- Bain & Company, a top global management consultancy, and Prysm Group, a leading economic consulting and corporate education firm, have announced a collaboration to expand corporate learning on web3 and emerging technologies.
  • "There is a costly gap between an organization's interest in staying at the forefront of emerging technologies and one's ability to do so," said Reed Cataldo, founding partner at Prysm Group.
  • Bain seeks to push the limits of the industry by supplying Prysm Group with invaluable insights from emerging technology efforts.
  • Prysm Group is an economic consulting and corporate learning firm focused on emerging technologies.

Chroma Medicine Welcomes Spark Therapeutics Co-Founder and Former Founding CEO Jeff Marrazzo to Board of Directors

Retrieved on: 
Tuesday, October 4, 2022
Civic, Neuromuscular Disorders, Bleeding, Jeanne Marrazzo, LinkedIn, Food, Drug discovery, CEO, Twitter, Multimedia, Wendell Pritchett, Gene expression, Harvard University, View, Retina, Hope, Civics, Spark, Medicine, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Sale, Patient, Board of directors, University, Spark Therapeutics, Lists of diseases, Board, Wharton School of the University of Pennsylvania, Pharmaceutical industry, Antibiotics, Chroma

CAMBRIDGE, Mass., Oct. 4, 2022 /PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 4, 2022 /PRNewswire/ -- Chroma Medicine , Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors.
  • "Jeff's leadership at Spark yielded the first-ever approved gene therapy, and we are thrilled to bring his expertise to the Chroma Board," said Catherine Stehman-Breen, M.D., CEO of Chroma.
  • His unique perspective as a gene therapy pioneer will be instrumental as we reimagine the future of genomic medicine."
  • Currently, Marrazzo serves on the Board of the Life Science Cares Philadelphia and the Rendell Center for Civics and Civic Engagement.

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

Retrieved on: 
Tuesday, October 4, 2022
Company, Cancer, Oncology, BS, Cedars-Sinai Medical Center, Santa Clara University, KRAS, HLA, Nasdaq, University, Therapy, Bristol Myers Squibb, Eli Lilly and Company, Merck Serono, Wendell Pritchett, Onyx Pharmaceuticals, Internal medicine, MBA, Antibody, Synthetic biology, Cytokine, Immune system, Merck, Eli Lilly, Patient, Mathematics, Merck Group, Compugen (Israeli company), Degenerative disease, Board of directors, Lightspeed Venture Partners, KIR, Immuno AG, Board, Sanofi, Amgen, Wharton School of the University of Pennsylvania, Pharmaceutical industry, Vaccine, Biology, MD

Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics.

Key Points: 
  • Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics.
  • "We are delighted to welcome Joe Leveque to our Board of Directors," said Sean R. Smith, Chief Executive Officer at ImmunOs Therapeutics.
  • "I am impressed by ImmunOs unique approach of developing HLA-based immune-modulating agents," said Joseph Leveque, MD, member of ImmunOs Therapeutics Board of Directors.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.

SWK Holdings Enhances Executive Management Team and Expands Underwriting Team

Retrieved on: 
Monday, October 3, 2022
Solution, Methodist University, Certified Fraud Examiner, BS, Certified Public Accountant, CFE, SEC, SOX, SWK, Tamas, Technology, Risk, Nasdaq, Form 10-K, Optimism, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Southern Methodist University, Certification, GAAP, Form, Wendell Pritchett, Cowen, MBA, Business administration, University, III, Growth, BCS, Initial public offering, Bachelor of Arts, Security (finance), CFO, San Francisco State University, Interim, Controller, Wachovia, IV, Deloitte, Board, Company, CPA, Wharton School of the University of Pennsylvania, Management, Finance

DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that the company has promoted Yvette Heinrichson to the role of Chief Financial Officer. Ms. Heinrichson was previously SWK's Chief Accounting Officer. SWK has also promoted John David ("J.D.") Tamas to Director of Underwriting, a newly created position at the company, and has hired Joe Moyer as an Associate.

Key Points: 
  • Mr. Staggs continued: "I would like to extend my sincerest gratitude to Charles Jacobson for his role in building SWK.
  • He has been a valued member of our leadership team since SWK's inception, and we wish him the best."
  • has an extensive credit background, and his enhanced role will allow SWK to increase underwriting throughput while maintaining strict credit standards.
  • He is a valuable member of our leadership team, and I'm pleased he is being recognized for his contributions to SWK."

Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

Retrieved on: 
Monday, October 3, 2022
Vaccine, OTC, Food, NASDAQ, Wendell Pritchett, NVAX, Drug development, Indian Institute of Technology (BHU) Varanasi, Microbiology, University, Research, CEO, Health, Adoption, Organic acid, Synthetic biology, Merck, Growth, Flagship Pioneering, Enzyme, Wharton School of the University of Pennsylvania, Institute, Biotechnology, MIT, Flagship, Bachelor of Engineering, Board of directors, Bachelor of Technology, Board, Therapy, GLOBE, Merck & Co., Fine chemical, Pharmaceutical industry, Codexis, Director, Technology

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors.
  • Rahul is a proven leader in the biopharmaceutical industry, with a demonstrated track record of enabling scale and accelerating the growth of innovative product pipelines, said Byron Dorgan, Chair of the Board of Codexis.
  • His insights and guidance across drug development and driving adoption of boundary-pushing technologies will prove invaluable throughout Codexis evolution, and we are fortunate to welcome him to our Board of Directors.
  • Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.

Venus Concept Announces Appointment of Rajiv De Silva as Chief Executive Officer and Director; Updates Fiscal Year 2022 Revenue Guidance

Retrieved on: 
Monday, October 3, 2022
Venus, Securities Act of 1933, BSE, GLOBE, Securities Exchange Act of 1934, Hair, Bausch Health, Wendell Pritchett, NASDAQ, Stanford University, Princeton University, Dermatology, University, MS, Industry, CEO, McKinsey & Company, Novartis, COVID-19, Annual report, Webcast, Growth, COO, Endo International, Â, Communication, Rajiv, Director, Leadership, Conference, Board, Company, ARTAS, Wharton School of the University of Pennsylvania, Management, Online gambling

The Company also announced the separation of Domenic Serafino as Chief Executive Officer and Director, effective October 2, 2022.

Key Points: 
  • The Company also announced the separation of Domenic Serafino as Chief Executive Officer and Director, effective October 2, 2022.
  • We are excited to have Rajiv join the Company to lead Venus Concept through its next stage of growth and development, said Scott Barry, Chairman and Director of Venus Concept.
  • Updated Fiscal Year 2022 Revenue Guidance:
    In connection with Rajiv De Silva's appointment as Chief Executive Officer, the Company has withdrawn its previously issued revenue guidance for fiscal year 2022, which was last updated on August 12, 2022.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD.